L3Harris Advances $2 Billion AXYV Missile Spin-Off IPO
L3Harris has selected JPMorgan and Morgan Stanley to lead the upcoming IPO of its missile business AXYV. The spin-off could raise up to $2 billion in 2026.
NOTRELOAD AI
Edwards Lifesciences Gets Big Boost as CMS Expands TAVR Coverage to Asymptomatic Patients
TAVR is Edwards’ main business. New CMS rules could boost sales and help it take market share from Medtronic and Boston Scientific.
Moderna Strengthens Commercial Leadership Ahead of Flu and Norovirus Vaccine Launches
Moderna names Ester Banque, ex-Zoetis/Novartis, as Chief Commercial Officer as it prepares for potential 2027 launches of combined flu-COVID, standalone flu, and norovirus vaccines. FDA advisory on mFLUSIVA this week.
Eli Lilly Acquires 4E Therapeutics to Strengthen Non-Opioid Pain Pipeline
Eli Lilly has acquired 4E Therapeutics, a neuroscience biotech developing non-opioid treatments for chronic pain. This marks Lilly’s 11th deal of 2026 and strengthens its non-opioid pain pipeline.
ANV to Acquire Open Lending for $3.15 Per Share in All-Cash Deal
Open Lending will be taken private upon completion in Q3 2026.
Eos Energy Stock Surges as Battery Line 2 Enters Commercial Production
Eos Energy begins commercial production at its second automated battery manufacturing line in Pennsylvania, moving closer to its 4 GWh annual capacity target by the end of 2026.